Catalyst Event
AbbVie Inc (ABBV) · Other
From KEDI Global Longevity Bio Index (KGLB)
4/28/2026, 12:00:00 AM
Announced a strategic agreement granting AbbVie an exclusive option to acquire Kestrel Therapeutics for up to $1.45 billion, centered on its pan-KRAS inhibitor KST-6051 for solid tumors.
Korean Translation
고형암 치료를 위한 pan-KRAS 억제제 KST-6051을 중심으로, 최대 14억 5천만 달러에 케스트럴 테라퓨틱스를 인수할 수 있는 독점적 옵션을 부여하는 전략적 계약을 발표함.
Related Recent Events
Biogen Inc (BIIB) · Other
FDA PDUFA target action date for LEQEMBI's subcutaneous autoinjector formulation (IQLIK SC-AI) for initiation dosing, a potential new administration option for the Alzheimer's disease treatment, scheduled for 2026-05-24. High impact expected due to the significant market potential of the Alzheimer's treatment.
5/24/2026, 12:00:00 AM
Thermo Fisher Scientific Inc (TMO) · Other
An Investor Day is scheduled for May 20, 2026, where senior management will provide presentations scheduled.
5/20/2026, 12:00:00 AM
Takeda Pharmaceutical Co Ltd (TAK) · Earnings Release
Takeda is scheduled to announce its financial results for the full fiscal year 2025 (ending March 31, 2026) on May 13, 2026. High importance is estimated as earnings reports for major pharmaceutical firms often trigger price movements exceeding 10% based on guidance. This event is scheduled.
5/13/2026, 12:00:00 AM
Natera Inc (NTRA) · Earnings Release
Q1 2026 earnings release is scheduled. Earnings announcements typically result in >5% price impact, scheduled.
5/7/2026, 12:00:00 AM
Viatris Inc (VTRS) · Earnings Release
Viatris is scheduled to report its first quarter 2026 financial results on May 7, 2026, with an estimated price impact of over 5% based on historical earnings volatility scheduled.
5/7/2026, 12:00:00 AM
Novo Nordisk A/S (NVO) · Earnings Release
Novo Nordisk is scheduled to announce its first quarter 2026 financial results. Low importance as it is a routine earnings call, scheduled.
5/6/2026, 12:00:00 AM